Trial Profile
Apixaban Discontinuation Prior to Major Surgery
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Haemorrhage
- Focus Pharmacokinetics
- Acronyms ADIOS
- 18 Mar 2019 Results assessing the proportion of patients demonstrating less than 30 ng/mL apixaban plasma concentration following at least 48-hours of apixaban discontinuation prior to surgery, were presented at the 68th Annual Scientific Session of the American College of Cardiology.
- 11 Sep 2018 Status changed from recruiting to completed.
- 25 Oct 2016 New trial record